analysis of winning advertisements
DESCRIPTION
Analysis of Winning Advertisements. Recap Past Studies Review Objectives Review Criteria Evaluate New Rx Performance for Winners Next Steps. Agenda. Does Journal Advertising Work? Does Advertising Have an Impact on Rxs? How Much Advertising is Necessary?. Perspective. - PowerPoint PPT PresentationTRANSCRIPT
![Page 1: Analysis of Winning Advertisements](https://reader036.vdocuments.mx/reader036/viewer/2022062521/5681684a550346895dde3913/html5/thumbnails/1.jpg)
Analysis of Winning Advertisements
![Page 2: Analysis of Winning Advertisements](https://reader036.vdocuments.mx/reader036/viewer/2022062521/5681684a550346895dde3913/html5/thumbnails/2.jpg)
Agenda
• Recap Past Studies• Review Objectives• Review Criteria• Evaluate New Rx Performance for Winners• Next Steps
![Page 3: Analysis of Winning Advertisements](https://reader036.vdocuments.mx/reader036/viewer/2022062521/5681684a550346895dde3913/html5/thumbnails/3.jpg)
Perspective
• Does Journal Advertising Work?• Does Advertising Have an Impact on Rxs?• How Much Advertising is Necessary?
![Page 4: Analysis of Winning Advertisements](https://reader036.vdocuments.mx/reader036/viewer/2022062521/5681684a550346895dde3913/html5/thumbnails/4.jpg)
Chronology and review of significant research
![Page 5: Analysis of Winning Advertisements](https://reader036.vdocuments.mx/reader036/viewer/2022062521/5681684a550346895dde3913/html5/thumbnails/5.jpg)
ROI Analysis of Pharmaceutical PromotionLandmark study historical data for 1995-99391 drugs, 16,696 monthly observationsDetermined marginal ROI
JAD, $5.00 +/- $0.88PME, $3.56 +/- $1.92DET, $1.72 +/- $0.19DTC, $0.19 +/- $0.52
Dartmouth Marginal ROI Study, 2001RAPP
![Page 6: Analysis of Winning Advertisements](https://reader036.vdocuments.mx/reader036/viewer/2022062521/5681684a550346895dde3913/html5/thumbnails/6.jpg)
• Analysis of ROI for Pharmaceutical Promotion– Extended data 1995-2000; 21,436 monthly observations– Examples of findings:
• $500M+/1998-2000: All tactics generate positive returns for average brand, but under spending on JAD and PME
– Additional spend on journals could have very positive returns for both small brands and large brands
Yale Marginal ROI Study, 2002ARPP
![Page 7: Analysis of Winning Advertisements](https://reader036.vdocuments.mx/reader036/viewer/2022062521/5681684a550346895dde3913/html5/thumbnails/7.jpg)
![Page 8: Analysis of Winning Advertisements](https://reader036.vdocuments.mx/reader036/viewer/2022062521/5681684a550346895dde3913/html5/thumbnails/8.jpg)
•Select targeted physician specialties•Oncology•Pulmonary Disease•Psychiatry•Neurology
![Page 9: Analysis of Winning Advertisements](https://reader036.vdocuments.mx/reader036/viewer/2022062521/5681684a550346895dde3913/html5/thumbnails/9.jpg)
• Analyze Top 10 Products for Each Specialty• Spend levels• Reach & Frequency Levels
![Page 10: Analysis of Winning Advertisements](https://reader036.vdocuments.mx/reader036/viewer/2022062521/5681684a550346895dde3913/html5/thumbnails/10.jpg)
Baseline Study10 month advertising campaign
Follow-up StudyEvaluate Results
![Page 11: Analysis of Winning Advertisements](https://reader036.vdocuments.mx/reader036/viewer/2022062521/5681684a550346895dde3913/html5/thumbnails/11.jpg)
Total of 203 insertions$1,083,466 in advertising space
•Oncology - $73,280•Pulmonary Disease - $91,925•Neurology - $99,639•Psych - $105,398•Primary Care - $432,577
![Page 12: Analysis of Winning Advertisements](https://reader036.vdocuments.mx/reader036/viewer/2022062521/5681684a550346895dde3913/html5/thumbnails/12.jpg)
Pulmonary Disease – 75%Psychiatry – 54%Oncology – 48%Neurology – 43%
Monthly ExposuresMonthly Exposures
![Page 13: Analysis of Winning Advertisements](https://reader036.vdocuments.mx/reader036/viewer/2022062521/5681684a550346895dde3913/html5/thumbnails/13.jpg)
Pulmonary Disease – 75%Psychiatry – 54%Oncology – 48%Neurology – 43%
Monthly ExposuresMonthly Exposures
![Page 14: Analysis of Winning Advertisements](https://reader036.vdocuments.mx/reader036/viewer/2022062521/5681684a550346895dde3913/html5/thumbnails/14.jpg)
Baseline Post-Campaign
Yes 24% 45%
No 74% 54%
Not Sure 2% 1%
The Awareness increased by 89%!
Are you aware of the availability of the Directory of Prescription Drug Patient Assistance Programs, from (PhRMA)?
![Page 15: Analysis of Winning Advertisements](https://reader036.vdocuments.mx/reader036/viewer/2022062521/5681684a550346895dde3913/html5/thumbnails/15.jpg)
• Neurologists were exposed least (43%/mo)– Awareness increased 69%
• Pulmonary Disease were exposed most (75%/mo)– Awareness increased by 117%
![Page 16: Analysis of Winning Advertisements](https://reader036.vdocuments.mx/reader036/viewer/2022062521/5681684a550346895dde3913/html5/thumbnails/16.jpg)
Two Product-Specific StudiesDesigned to measure the relationship of detailing and print advertising
![Page 17: Analysis of Winning Advertisements](https://reader036.vdocuments.mx/reader036/viewer/2022062521/5681684a550346895dde3913/html5/thumbnails/17.jpg)
• Select two products in major therapeutic areas– No previous PCP promotion– Patent-protected– One year test period
![Page 18: Analysis of Winning Advertisements](https://reader036.vdocuments.mx/reader036/viewer/2022062521/5681684a550346895dde3913/html5/thumbnails/18.jpg)
• Four Cells of 16,000 PCP’s– Control Group– Low level of promotion– Average level of promotion– High level of promotion
![Page 19: Analysis of Winning Advertisements](https://reader036.vdocuments.mx/reader036/viewer/2022062521/5681684a550346895dde3913/html5/thumbnails/19.jpg)
• Pretest each advertisement• Launch Campaigns• Six Month PosTest
– Ad Recognition– Product Recall– Correct Message Association– New Rx’s
• New Rx Analysis• Twelve Month Results
![Page 20: Analysis of Winning Advertisements](https://reader036.vdocuments.mx/reader036/viewer/2022062521/5681684a550346895dde3913/html5/thumbnails/20.jpg)
• “B” PreTest– 57% physicians unsure/negative
• too busy, too crowded, too much information– Recommended to change ad size from 2 pages to 4 pages– Not Done
• Subsequent change of detail message
![Page 21: Analysis of Winning Advertisements](https://reader036.vdocuments.mx/reader036/viewer/2022062521/5681684a550346895dde3913/html5/thumbnails/21.jpg)
Metrics did not change: PCP NRx
Mar-Aug ‘03 Mar-Aug ‘04 % Change
Control 5,707 8,287 45.2%
Cell I 5,438 7,845 44.3%
Cell II 5.946 8,718 46.5%
Cell III 6,713 9,650 43.8%
![Page 22: Analysis of Winning Advertisements](https://reader036.vdocuments.mx/reader036/viewer/2022062521/5681684a550346895dde3913/html5/thumbnails/22.jpg)
• “A” PreTest– Good pretest acceptance– Accepted visual elements– Accepted headline
• Recommended message simplification– adjusted
![Page 23: Analysis of Winning Advertisements](https://reader036.vdocuments.mx/reader036/viewer/2022062521/5681684a550346895dde3913/html5/thumbnails/23.jpg)
1116
23
44
05
1015202530354045
Control Low Cell Average Cell High Cell
Product Recall – six months
![Page 24: Analysis of Winning Advertisements](https://reader036.vdocuments.mx/reader036/viewer/2022062521/5681684a550346895dde3913/html5/thumbnails/24.jpg)
21
44 45
58
0
10
20
30
40
50
60
Control Low Cell Average Cell High Cell
Ad Recognition – six months
![Page 25: Analysis of Winning Advertisements](https://reader036.vdocuments.mx/reader036/viewer/2022062521/5681684a550346895dde3913/html5/thumbnails/25.jpg)
05
1015202530354045
Control Low Cell Average Cell High Cell
3229 26
44
Correct Message Association – six months
![Page 26: Analysis of Winning Advertisements](https://reader036.vdocuments.mx/reader036/viewer/2022062521/5681684a550346895dde3913/html5/thumbnails/26.jpg)
0
20
40
60
Control Low Cell Average Cell High Cell
..
40% 40% 41% 42%
43% 38%46% 52%
Company Records
Physicians’ Perception
Perception of Detailing – six months
![Page 27: Analysis of Winning Advertisements](https://reader036.vdocuments.mx/reader036/viewer/2022062521/5681684a550346895dde3913/html5/thumbnails/27.jpg)
First Choice Therapy
31 3032
38
0
5
10
15
20
25
30
35
40
Percent
Control Cell 1 Cell 2 Cell 3
Product “A” Six Month PosTest
![Page 28: Analysis of Winning Advertisements](https://reader036.vdocuments.mx/reader036/viewer/2022062521/5681684a550346895dde3913/html5/thumbnails/28.jpg)
0.1
9.79
0.1
11.07
02468
1012
% change
1st 6 Months 2nd 6 Months
ControlHigh cell
Change in NRx
![Page 29: Analysis of Winning Advertisements](https://reader036.vdocuments.mx/reader036/viewer/2022062521/5681684a550346895dde3913/html5/thumbnails/29.jpg)
9.79
11.07 11.16
9
9.5
10
10.5
11
11.5
% change
1st 6Months
2nd 6Months
Post TestPeriod
High cell
(8 months)
Change in NRx
![Page 30: Analysis of Winning Advertisements](https://reader036.vdocuments.mx/reader036/viewer/2022062521/5681684a550346895dde3913/html5/thumbnails/30.jpg)
Doctor’s Choice Awards
![Page 31: Analysis of Winning Advertisements](https://reader036.vdocuments.mx/reader036/viewer/2022062521/5681684a550346895dde3913/html5/thumbnails/31.jpg)
Journal Advertisement Attributes – Doctors’ Choice Questionnaire
• Prompts seeking more information or re-examination of treatment• Helps with clinical decisions• Adds to information provided by company representative
• Has immediate appeal to gain interestHas immediate appeal to gain interest• Communicates clearly and quickly
• Reminds about value of product prescribed
![Page 32: Analysis of Winning Advertisements](https://reader036.vdocuments.mx/reader036/viewer/2022062521/5681684a550346895dde3913/html5/thumbnails/32.jpg)
Doctor's Choice Awards 2006
• Majority of winning advertisement achieved increased New Rx's
![Page 33: Analysis of Winning Advertisements](https://reader036.vdocuments.mx/reader036/viewer/2022062521/5681684a550346895dde3913/html5/thumbnails/33.jpg)
Doctor's Choice Awards 2007
• Newest findings
![Page 34: Analysis of Winning Advertisements](https://reader036.vdocuments.mx/reader036/viewer/2022062521/5681684a550346895dde3913/html5/thumbnails/34.jpg)
![Page 35: Analysis of Winning Advertisements](https://reader036.vdocuments.mx/reader036/viewer/2022062521/5681684a550346895dde3913/html5/thumbnails/35.jpg)
Once again, the overwhelming majority of winners gained New Rx marketshare
New Rx's data contributed by VerispanReach & Frequency data contributed by MARS Medical
![Page 36: Analysis of Winning Advertisements](https://reader036.vdocuments.mx/reader036/viewer/2022062521/5681684a550346895dde3913/html5/thumbnails/36.jpg)
Lipitor
0.00%
5.00%
10.00%
15.00%
20.00%
25.00%
30.00%
35.00%
40.00%
CardiovascularsCardiovasculars
![Page 37: Analysis of Winning Advertisements](https://reader036.vdocuments.mx/reader036/viewer/2022062521/5681684a550346895dde3913/html5/thumbnails/37.jpg)
Lipitor
73
84
80
76
66687072747678808284
GP FP IM CA
*This is read as 76% of the Card universe was exposed *This is read as 76% of the Card universe was exposed to the Lipitor ad each month of the campaignto the Lipitor ad each month of the campaign
![Page 38: Analysis of Winning Advertisements](https://reader036.vdocuments.mx/reader036/viewer/2022062521/5681684a550346895dde3913/html5/thumbnails/38.jpg)
Zovirax
0.00%
0.02%
0.04%
0.06%
0.08%
0.10%
0.12%
Generic environmentGeneric environment
DermatologicalsDermatologicals
![Page 39: Analysis of Winning Advertisements](https://reader036.vdocuments.mx/reader036/viewer/2022062521/5681684a550346895dde3913/html5/thumbnails/39.jpg)
Zovirax
54
0
10
20
30
40
50
60
Derm
![Page 40: Analysis of Winning Advertisements](https://reader036.vdocuments.mx/reader036/viewer/2022062521/5681684a550346895dde3913/html5/thumbnails/40.jpg)
Novolog FlexPen
0.00%
0.50%
1.00%
1.50%
2.00%
2.50%
DiabetesDiabetes
![Page 41: Analysis of Winning Advertisements](https://reader036.vdocuments.mx/reader036/viewer/2022062521/5681684a550346895dde3913/html5/thumbnails/41.jpg)
Novolog FlexPen
49
05101520253035404550
Diabetes/Endo
![Page 42: Analysis of Winning Advertisements](https://reader036.vdocuments.mx/reader036/viewer/2022062521/5681684a550346895dde3913/html5/thumbnails/42.jpg)
Zyvox
0.00%
0.02%
0.04%
0.06%
0.08%
0.10%
0.12%
Amoxicillin in group
Anti-InfectivesAnti-Infectives
![Page 43: Analysis of Winning Advertisements](https://reader036.vdocuments.mx/reader036/viewer/2022062521/5681684a550346895dde3913/html5/thumbnails/43.jpg)
Zyvox
82
0102030405060708090
ID
![Page 44: Analysis of Winning Advertisements](https://reader036.vdocuments.mx/reader036/viewer/2022062521/5681684a550346895dde3913/html5/thumbnails/44.jpg)
Halflytely
0.00%
5.00%
10.00%
15.00%
20.00%
25.00%
GastroenterologicalsGastroenterologicals
![Page 45: Analysis of Winning Advertisements](https://reader036.vdocuments.mx/reader036/viewer/2022062521/5681684a550346895dde3913/html5/thumbnails/45.jpg)
Halflytely
62
0
10
20
30
40
50
60
70
Gastro
![Page 46: Analysis of Winning Advertisements](https://reader036.vdocuments.mx/reader036/viewer/2022062521/5681684a550346895dde3913/html5/thumbnails/46.jpg)
Keppra
0.00%
0.50%
1.00%
1.50%
2.00%
2.50%
NeurologicalsNeurologicals
![Page 47: Analysis of Winning Advertisements](https://reader036.vdocuments.mx/reader036/viewer/2022062521/5681684a550346895dde3913/html5/thumbnails/47.jpg)
Keppra
62
0
10
20
30
40
50
60
70
Neuro
![Page 48: Analysis of Winning Advertisements](https://reader036.vdocuments.mx/reader036/viewer/2022062521/5681684a550346895dde3913/html5/thumbnails/48.jpg)
NuvaRing
0.00%
1.00%
2.00%
3.00%
4.00%
5.00%
6.00%
7.00%
Obstetricals/GynecologicalsObstetricals/Gynecologicals
![Page 49: Analysis of Winning Advertisements](https://reader036.vdocuments.mx/reader036/viewer/2022062521/5681684a550346895dde3913/html5/thumbnails/49.jpg)
NuvaRing
73
0
10
20
30
40
50
60
70
80
OB/GYN
![Page 50: Analysis of Winning Advertisements](https://reader036.vdocuments.mx/reader036/viewer/2022062521/5681684a550346895dde3913/html5/thumbnails/50.jpg)
Tarceva
0.00%
0.20%
0.40%
0.60%
0.80%
1.00%
1.20%
OncologicalsOncologicals
![Page 51: Analysis of Winning Advertisements](https://reader036.vdocuments.mx/reader036/viewer/2022062521/5681684a550346895dde3913/html5/thumbnails/51.jpg)
Tarceva
83
0102030405060708090
Oncologists
![Page 52: Analysis of Winning Advertisements](https://reader036.vdocuments.mx/reader036/viewer/2022062521/5681684a550346895dde3913/html5/thumbnails/52.jpg)
Gardasil
0
0.05
0.1
0.15
0.2
0.25
PediatricsPediatrics
![Page 53: Analysis of Winning Advertisements](https://reader036.vdocuments.mx/reader036/viewer/2022062521/5681684a550346895dde3913/html5/thumbnails/53.jpg)
Gardasil
5760
36
54
0
10
20
30
40
50
60
GP FP IM Ped
![Page 54: Analysis of Winning Advertisements](https://reader036.vdocuments.mx/reader036/viewer/2022062521/5681684a550346895dde3913/html5/thumbnails/54.jpg)
Lunesta
12.00%
12.50%
13.00%
13.50%
14.00%
14.50%
15.00%
PsychiatricsPsychiatrics
![Page 55: Analysis of Winning Advertisements](https://reader036.vdocuments.mx/reader036/viewer/2022062521/5681684a550346895dde3913/html5/thumbnails/55.jpg)
Lunesta
73
85
7468
47
0102030405060708090
GP FP IM PSY OB
![Page 56: Analysis of Winning Advertisements](https://reader036.vdocuments.mx/reader036/viewer/2022062521/5681684a550346895dde3913/html5/thumbnails/56.jpg)
Flomax
36.00%36.50%37.00%37.50%38.00%38.50%39.00%39.50%40.00%40.50%41.00%
UrologicalUrological
![Page 57: Analysis of Winning Advertisements](https://reader036.vdocuments.mx/reader036/viewer/2022062521/5681684a550346895dde3913/html5/thumbnails/57.jpg)
Flomax
88
0102030405060708090
Uro
![Page 58: Analysis of Winning Advertisements](https://reader036.vdocuments.mx/reader036/viewer/2022062521/5681684a550346895dde3913/html5/thumbnails/58.jpg)
Conclusions
• Identify effective messages/creative • Measure New Rx’s Over Time• Successful messages are effective with ample execution
The winning products continue to demonstrate success in recognition and performance